The privately-owned company, supporting global clinical trials of various pharmaceutical companies across multiple therapeutic areas, has signed a long-term lease contract for a 900 sqm office space, according to a statement sent to budapestbusinessjournal.com. The recently renovated building is located across the street from the new Museum of Ethnography in City Park.
“With multiple award-winning offices across Europe, we also aspire to create a top-quality workspace for our colleagues in Budapest that will enable them to deliver on our motto of being ‘the global CRO where clinical trials run on time,’” said Yuri A. Titov, director of clinical operations and country manager at PSI.
“Our new office in the Hungarian capital will trigger creativity and collaboration with a fit-out that not only contributes to personal wellbeing but also supports teamwork and boosts efficiency,” he added.
Máté Bihari, leasing and sales director at Horizon Development, added, “We were delighted to lead the lease negotiation process of PSI CRO that led to their long-term commitment to Park Atrium as their new center in Budapest. Our already diverse tenant mix became even richer with this prestigious clinical research company.”
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
